Browsing Tag
ASN Kidney Week
1 post
Can povetacicept reshape autoimmune kidney care? Vertex Pharmaceuticals’ RUBY-3 trial shows promise
Vertex’s RUBY-3 trial shows strong 48-week data for povetacicept in IgAN and pMN. Find out how this sets the stage for late-stage trials and regulatory filings.